TMB-003 Therapy to Reduce Scarring Wins FDA Orphan Drug Designation

TMB-003 Therapy to Reduce Scarring Wins FDA Orphan Drug Designation

282947

TMB-003 Therapy to Reduce Scarring Wins FDA Orphan Drug Designation

Scleroderma treatment TMB-003, which aims to improve patients’ quality of life by reducing the scarring that characterizes the autoimmune disorder, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). This designation is awarded to investigational therapies intended to improve treatment for rare diseases, defined as conditions that affect fewer than 200,000 people in the U.S. The designation comes with certain incentives, including tax credits for clinical testing and — if…

You must be logged in to read/download the full post.